Brainstorm Cell Therapeutics (BCLI)
0.53
-0.02 (3.64%)
Upcoming Events
Latest Headlines
Form 3 BRAINSTORM CELL THERAPEU For: Apr 17 Filed by: Dagher Ibrahim B.
April 22, 2024 8:07 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Apr 17 Filed by: Lebovits Chaim
April 19, 2024 6:07 AM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) Announces Resignation of Co-CEO Stacy Lindborg
April 17, 2024 6:07 AM - StreetInsider
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 16
April 17, 2024 6:02 AM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) Announces Management Changes
April 17, 2024 5:42 AM - StreetInsider
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
April 16, 2024 6:31 PM - PR NewsWire
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 10
April 11, 2024 6:11 AM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) Regains Nasdaq Compliance
April 11, 2024 6:01 AM - StreetInsider
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
April 11, 2024 6:00 AM - PR NewsWire
Brainstorm Cell Therapeutics (BCLI) Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
April 10, 2024 6:01 AM - StreetInsider
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
April 10, 2024 6:00 AM - PR NewsWire
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 09
April 9, 2024 6:05 AM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
April 9, 2024 6:01 AM - StreetInsider
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
April 9, 2024 6:00 AM - PR NewsWire
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
April 8, 2024 6:00 AM - PR NewsWire
Form 424B5 BRAINSTORM CELL THERAPEU
April 2, 2024 4:21 PM - SEC Filing
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 02
April 2, 2024 4:16 PM - SEC Filing
Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31
April 1, 2024 9:16 AM - SEC Filing
Form 8-K BRAINSTORM CELL THERAPEU For: Apr 01
April 1, 2024 8:16 AM - SEC Filing
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
April 1, 2024 8:05 AM - PR NewsWire
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lindborg Stacy
March 13, 2024 8:58 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Yablonka Uri
March 13, 2024 8:57 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Patlis Alla
March 13, 2024 8:56 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lebovits Chaim
March 13, 2024 8:55 PM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference
February 27, 2024 6:32 AM - StreetInsider
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
February 27, 2024 6:30 AM - PR NewsWire
Brainstorm Cell Therapeutics (BCLI) Submits SPA Request to FDA for US Phase 3b Trial of NurOwn
February 23, 2024 6:00 AM - StreetInsider
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
February 23, 2024 6:00 AM - PR NewsWire
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
February 13, 2024 6:30 AM - PR NewsWire
Form SC 13G/A BRAINSTORM CELL THERAPEU Filed by: Ness Kevin Dean
February 12, 2024 10:06 AM - SEC Filing
Full Article List
